IL17A and psoriasis: However, a key concern especially with systemic IL-17 blockade is safety as multiple clinical trials (e.g., in psoriasis) showed a significantly increased risk of mucocutaneous candidiasis (oral, cutaneous, and oropharyngeal) with IL-17 inhibitors compared with placebo or non-IL-17 biologics [109,110].